Pentacosafluorotridecanoic Acid

Synonyms: PFTrDA
Pentacosafluorotridecanoic Acid (PFTrDA) 是一种具有强内分泌干扰活性的长链全氟烷基羧酸,具有雌激素效应,会干扰雄性斑马鱼中 vtg1 的转录以及性激素稳态,并以性别依赖模式干扰类固醇生成和 HPG 轴功能,还可抑制 CYP17A 和 CYP11A1,从而降低 H295R 细胞中的睾酮水平并提高 E2/T 比值,同时在产前暴露后会引发性别特异性免疫调节,并与女婴较低的湿疹风险相关,因此可用于内分泌干扰和湿疹相关研究。
产品编号: MS-W50522 纯度: 95.0% CAS No.: 72629-94-8 分子式: C₁₃Hf₂₅O₂ 分子量: 664.11
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

Pentacosafluorotridecanoic Acid (PFTrDA) 是一种具有强内分泌干扰活性的长链全氟烷基羧酸,具有雌激素效应,会干扰雄性斑马鱼中 vtg1 的转录以及性激素稳态,并以性别依赖模式干扰类固醇生成和 HPG 轴功能,还可抑制 CYP17A 和 CYP11A1,从而降低 H295R 细胞中的睾酮水平并提高 E2/T 比值,同时在产前暴露后会引发性别特异性免疫调节,并与女婴较低的湿疹风险相关,因此可用于内分泌干扰和湿疹相关研究。

生物实验数据

生物活性 Pentacosafluorotridecanoic Acid (PFTrDA) is a long-chain perfluoroalkyl carboxylic acid with strong endocrine-disrupting activity that exerts estrogenic effects, interferes with vtg1 transcription and sex hormone homeostasis in male zebrafish, disrupts steroidogenesis and HPG axis function in a sex-dependent manner, inhibits CYP17A and CYP11A1 to reduce testosterone levels and increase the E2/T ratio in H295R cells, induces sex-specific immunomodulation after prenatal exposure, is associated with a lower risk of eczema in female infants, and can be used for research on endocrine disruption and eczema.
IC50 & Target

CYP17

 

CYP11A1

 

体外研究
(In Vitro)

Pentacosafluorotridecanoic Acid (0.05-50 mg/L; 48 h) 可改变 H295R 人肾上腺皮质癌细胞中的类固醇激素平衡并下调关键类固醇生成基因。

体内研究
(In Vivo)

Pentacosafluorotridecanoic Acid (0.01-10 mg/L; waterborne; continuous; 120 days) 可诱导斑马鱼产生性别依赖性内分泌干扰,包括雄性斑马鱼体内 E2 水平及 E2/T、E2/11-KT 比值升高,雌性斑马鱼体内 vtg1 表达下调,各生命阶段存活率降低,以及下丘脑-垂体-性腺 (HPG) 轴基因表达改变。

Animal Model: neonates (< 24 h old)
Dosage: 0.78 μg/L, 3.13 μg/L, 12.5 μg/L, 50 μg/L, 200 μg/L (chronic exposure); 1 mg/L, 10 mg/L, 100 mg/L (acute exposure)
Administration: waterborne; continuous; 21 days (chronic exposure); waterborne; continuous; 48 hours (acute exposure)
Result: Determined 48-hour EC50 for immobilization as 8.23 mg/L.
Identified NOEC for immobilization as 1 mg/L and LOEC as 10 mg/L for 48-hour acute exposure.
Established survival NOEC as 0.0125 mg/L for 21-day chronic exposure.
Significantly delayed the time required for reproduction of the first brood at 0.2 mg/L exposure.
Decreased population growth rate in a dose-dependent manner during 21-day chronic exposure.
Animal Model: Danio rerio (> 3 month old adults, fertilized eggs/larvae/juveniles)
Dosage: 0.01 mg/L, 0.1 mg/L, 1 mg/L, 10 mg/L
Administration: waterborne; continuous; from fertilization through 120 dpf
Result: Identified NOEC for survival as 0.01 mg/L across larvae, juvenile, and adult stages, reduced adult survival to 40.63% at 0.1-10 mg/L, and increased condition factor of adult fish at 0.1 mg/L.
Elevated 17β-estradiol (E2) in male fish at 0.01 mg/L, decreased testosterone (T) and 11-ketotestosterone (11-KT) at 0.1 mg/L, and increased E2/T and E2/11-KT ratios at ≥ 0.01 mg/L.
Upregulated GnRHR2, GnRHR4, and ERα mRNA in male brain, GnRHR2 mRNA in female brain, HMGRB, 3βHSD, and CYP11A mRNA in female gonad.
Downregulated VTG1 mRNA in female liver concentration-dependently and up-regulated CYP19A and VTG1 mRNA in male gonad/liver at 0.1 mg/L.
Animal Model: Danio rerio (mixed sex, starting as fertilized eggs, raised to adult stage (120 day post fertilization))
Dosage: 0.01 mg/L; 0.1 mg/L; 1 mg/L; 10 mg/L
Administration: waterborne; continuous; 120 days
Result: Elevated 17β-estradiol (E2), E2/T ratio, E2/11-KT ratio and gnrhr4 mRNA in male zebrafish at 0.01 mg/L.
Down-regulated vtg1 mRNA concentration-dependently and up-regulated hmgrb mRNA in female zebrafish at 0.01 mg/L.
Reduced zebrafish survival dose-dependently with stage-specific NOECs and increased condition factor in 120 dpf adults.
性状 固体
颜色 White to off-white

化学信息

分子量 664.11
分子式 C₁₃Hf₂₅O₂
CAS No. 72629-94-8
别名 PFTrDA

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础